Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci 2008;99:1180-1187.Sueoka-Aragane, N.; Imai, K.; Komiya, K.; Sato, A.; Tomimasu, R.; Hisatomi, T.; Sakuragi, T.; Mitsuoka, M.; Hayashi, S.; Nakachi, K.; Sueoka, E. Exon 19 of ...
Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases. Ann Thorac Surg 2020. 9. Renaud S, Seitlinger J, Guerrera F et al. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell ...
[1]Huang, Le-Tian, et al. "Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in EGFR-TKI-Treated Advanced Non-Small-Cell Lung Cancer." Lung Cancer (2022). [2]Grant MJ, Aredo JV, Starrett JH, St...
Non Small Cell Lung Cancer Pharmacology, Toxicology and Pharmaceutical Science 100% Exon 19 Deletion mutation Keyphrases 100% Overall Survival Biochemistry, Genetics and Molecular Biology 33% Somatic Mutation Biochemistry, Genetics and Molecular Biology 11% View full fingerprint Cite this ...
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer[J] . Victor H.F. Lee,Vicky P.C. Tin,Tim-shing Choy,Ka-on Lam,Cheuk-wai Choi,Lap-ping Chung,Janice W.H. Tsang,Patty P.Y. ...
We read with interest the recently published paper by Truini and colleagues ([1][1]) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750>P mutation. We reviewed our patient database and found 6 cases out of 265 with...
EGFR mutations in lung cancer : A morphological, immunohistochemical and molecular study of lung adenocarcinoma EGFR exon 19 deletionEGFR exon 21 L858R point mutationLung adenocarcinomaNecrosisImmunohistochemistryThe study of epidermal growth factor receptor mutations has ... M Verdu,I Trias,R Roman,......
AENEAS研究 [2] ,对比阿美替尼和吉非替尼一线治疗EGFR经典突变(exon19Del或exon21L858R)局部晚期或转移性NSCLC患者的疗效和安全性。结果显示,与吉非替尼相比,阿美替尼显著延长PFS(19.3个月 vs 9.9个月)和DoR(18.1个月 vs 8.3个月)。安全性方面,阿美替尼治疗患者治疗相关严重不良事件相较于吉非替尼发生率更低...
AENEAS研究 [2] ,对比阿美替尼和吉非替尼一线治疗EGFR经典突变(exon19Del或exon21L858R)局部晚期或转移性NSCLC患者的疗效和安全性。结果显示,与吉非替尼相比,阿美替尼显著延长PFS(19.3个月 vs 9.9个月)和DoR(18.1个月 vs 8.3个月)。安全性方面,阿美替尼治疗患者治疗相关严重不良事件相较于吉非替尼发生率更低...
摘要: BackgroundThe purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases.关键词: Erlotinib, Gefitinib, Lung adenocarcinoma, Overall survival ...